Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.
about
Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsCalcium regulation and bone mineral metabolism in elderly patients with chronic kidney diseaseArtificial receptors for the recognition of phosphorylated moleculesMedication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis providerCalciphylaxis: emerging concepts in prevention, diagnosis, and treatmentHomozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient miceThe Diet and Haemodialysis Dyad: Three Eras, Four Open Questions and Four Paradoxes. A Narrative Review, Towards a Personalized, Patient-Centered Approach.Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease.Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis StudyCompounds in development to combat hyperphosphataemia.The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure.How can the cardiac death rate be reduced in dialysis patients?Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patientsThe roles of the skeleton and phosphorus in the CKD mineral bone disorderEfficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic reviewNephrology: 4. Strategies for the care of adults with chronic kidney disease.The role of autophagy in vascular biology.Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells.Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease.Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysisRelationship of missed and shortened hemodialysis treatments to hospitalization and mortality: observations from a US dialysis network.Effects of percutaneous ethanol injection therapy on subsequent surgical parathyroidectomyThe Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS.Secondary hyperparathyroidism disease stabilization following calcimimetic therapy.Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cellsCalcium agonists in hyperparathyroidism.The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysisCalcimimetics and the treatment of primary and secondary hyperparathyroidism.Medical and surgical treatment for secondary and tertiary hyperparathyroidism.Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis.Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.Comparison of total parathyroidectomy without autotransplantation and without thymectomy versus total parathyroidectomy with autotransplantation and with thymectomy for secondary hyperparathyroidism: TOPAR PILOT-Trial.Nocturnal eating disturbs phosphorus excretion in young subjects: a randomized crossover trial.Hemodialysis in children: general practical guidelines.The safety of phosphate binders.Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismA randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patientsVitamin K status and vascular calcification: evidence from observational and clinical studies.Surgical treatment of secondary hyperparathyroidism due to chronic kidney disease.
P2860
Q24244049-8BA64D9C-DE02-4A30-9876-FD2A4A297C73Q26863412-8D64084B-414F-4DAD-BA3A-89E3909B0CB6Q27001011-610AB53D-C368-4A14-B0A3-5E99B8491FD0Q28168531-A7913665-DF55-4920-8523-3234089CE9E9Q28213077-6C42C9CA-F237-47E2-A1A2-3A6D87D7EC78Q28507303-A4AEDE2D-1FAD-41CB-9A17-5ED0E6ABF060Q33616803-41961263-4508-4159-ADDD-BC4B5876ABECQ33874058-A6C75C24-612B-4F89-9AEC-1632E74CDEBFQ33994155-06EE468B-854C-4DBE-8C39-9EAF206B5904Q34481935-87302F68-7BB5-4AC3-A648-DDA6C0512BEDQ34506934-06C6FBA4-65DB-4365-87CE-8B579576072AQ34549918-374DC375-B2C6-4738-81E6-AAA672C0887CQ34590350-D915F068-41B0-4EBE-ABED-FEECEC03966BQ35013304-F6688BDA-E464-47B5-96A4-6AEB29DD9B52Q35019709-5F00495A-8CAA-4AD5-B3BD-7BAE0DCAFE1EQ35031111-7D05082C-1C60-468D-980D-5B0A4BED4171Q35037113-F71F1942-35BA-4306-BF1B-80B8CF6957F5Q35107539-1FB82739-2A57-4CB2-AF26-497B1C7498ACQ35249551-9B508147-F97A-499C-858D-528DC1A308C1Q35351243-36C7718D-E22E-4FC2-BE99-32F6406F07DEQ35366611-E7FAD8FA-B388-4CB8-A34D-4CDB7C641CDFQ35573596-BA30065C-1009-4620-9843-22C6D3CFF5BFQ35573642-9A965BE0-3844-44E3-AE9A-14B180D81804Q35573653-EA0552DB-9D9E-41F2-B7C1-268B9739A8F1Q35669331-F4FFF99F-4417-4EAF-87D4-F42530390076Q35688223-0289174D-DB81-4ADF-87FA-3DE0D457990BQ35826159-A97DCCCB-1144-4A4B-AD51-A2C7200B4FE3Q35915930-64F1EA83-AE02-494F-8BF9-30929FD2EA7AQ36013623-2DAE169C-BEAA-40D9-97C4-3736E47A08C5Q36061887-551AF248-5676-4CB9-B38B-58BCD81C9435Q36066111-1DFD2E89-6E22-4DA2-9808-639617DD781CQ36138126-960723E0-5EFC-457D-B51C-1EF2CD3CD5A7Q36142210-034B732A-6523-484E-9F39-A93422022948Q36158150-BDD4187E-1F31-48BD-AF9D-2F92DFE759B3Q36565049-0E650322-EBCA-4BD4-96DD-671D7D7F74C8Q36567144-EB2936F8-E246-4394-9C62-475951C692F4Q36666922-48324937-67CD-45FB-A146-15814410358BQ36736674-5BE8121C-E13D-400D-B2BA-43B9A38A7102Q36828717-A9363C66-0D3F-4220-A215-C0A9C7B25471Q36853299-23B1E7F5-6B4A-4A14-B1FE-CB5D838B071C
P2860
Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Re-evaluation of risks associa ...... ns for a change in management.
@ast
Re-evaluation of risks associa ...... ns for a change in management.
@en
type
label
Re-evaluation of risks associa ...... ns for a change in management.
@ast
Re-evaluation of risks associa ...... ns for a change in management.
@en
prefLabel
Re-evaluation of risks associa ...... ns for a change in management.
@ast
Re-evaluation of risks associa ...... ns for a change in management.
@en
P1476
Re-evaluation of risks associa ...... ns for a change in management.
@en
P2093
P304
P356
10.1016/S0272-6386(00)70064-3
P577
2000-06-01T00:00:00Z